CytomX Therapeutics announced that it has received clearance from the U.S. Food and Drug Administration, FDA, for its Investigational New Drug, IND, applications for the conditionally activated Probody therapeutics CX-2051, an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b. CX-2051 has been cleared for the initiation of Phase 1 dose escalation in solid tumors with known EpCAM expression and CX-801 has been cleared for the initiation of Phase 1 dose escalation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma. Both programs are expected to start Phase 1 studies in the first half of 2024. “CX-2051 and CX-801 have the potential to address major unmet needs in oncology and we are excited to advance these programs into Phase 1 clinical studies. CX-2051 is an ADC conjugated to a next-generation topoisomerase-1 inhibitor payload that we believe is tailored to certain EpCAM-expressing tumors, including colorectal cancer,” said Wayne Chu, M.D., chief medical officer of CytomX Therapeutics. “CX-801 is designed to overcome previous limitations of interferon-directed therapies due to systemic toxicity and establish CX-801 as a cornerstone of combination regimens, including with checkpoint inhibitors, across a wide range of tumor types,” continued Dr. Chu.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
- CytomX Therapeutics announces 2024 anticipated milestones, cash runway
- CytomX Therapeutics announces 2024 company priorities
- CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
- CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference